Cargando…
Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling
Ovarian cancer is the most lethal malignancy with depressive 5-year survival rate, mainly due to patients with advanced stages experience tumor recurrence and resistance to the current chemotherapeutic agents. Thus, exploring the underlying molecular mechanisms involved in chemo-resistance is crucia...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161906/ https://www.ncbi.nlm.nih.gov/pubmed/35465837 http://dx.doi.org/10.1080/21655979.2022.2064652 |
_version_ | 1784719582467981312 |
---|---|
author | Liang, Suiying Liu, Yueyang He, Jianhui Gao, Tian Li, Lanying He, Shanyang |
author_facet | Liang, Suiying Liu, Yueyang He, Jianhui Gao, Tian Li, Lanying He, Shanyang |
author_sort | Liang, Suiying |
collection | PubMed |
description | Ovarian cancer is the most lethal malignancy with depressive 5-year survival rate, mainly due to patients with advanced stages experience tumor recurrence and resistance to the current chemotherapeutic agents. Thus, exploring the underlying molecular mechanisms involved in chemo-resistance is crucial for management of treatment to improve therapeutic outcomes. In the current study, we found overexpression of FAM46A in ovarian cancer patients demonstrated an aggressive phenotype and poor outcome. Furthermore, FAM46A overexpression in ovarian cancer cells induces higher CDDP resistance. However, inhibition of FAM46A sensitized ovarian cancer cell lines to CDDP cytotoxicity both in vitro and in vivo. Mechanically, upregulation of FAM46A activated transforming growth factor-β (TGF-β)/Smad signaling and upregulated the levels of nuclear Smad2. Taken together, our results highlight the important oncogenic role of FAM46A in ovarian cancer progression and might provide a potential clinical target for patients with chemo resistant ovarian cancer. |
format | Online Article Text |
id | pubmed-9161906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91619062022-06-03 Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling Liang, Suiying Liu, Yueyang He, Jianhui Gao, Tian Li, Lanying He, Shanyang Bioengineered Research Paper Ovarian cancer is the most lethal malignancy with depressive 5-year survival rate, mainly due to patients with advanced stages experience tumor recurrence and resistance to the current chemotherapeutic agents. Thus, exploring the underlying molecular mechanisms involved in chemo-resistance is crucial for management of treatment to improve therapeutic outcomes. In the current study, we found overexpression of FAM46A in ovarian cancer patients demonstrated an aggressive phenotype and poor outcome. Furthermore, FAM46A overexpression in ovarian cancer cells induces higher CDDP resistance. However, inhibition of FAM46A sensitized ovarian cancer cell lines to CDDP cytotoxicity both in vitro and in vivo. Mechanically, upregulation of FAM46A activated transforming growth factor-β (TGF-β)/Smad signaling and upregulated the levels of nuclear Smad2. Taken together, our results highlight the important oncogenic role of FAM46A in ovarian cancer progression and might provide a potential clinical target for patients with chemo resistant ovarian cancer. Taylor & Francis 2022-04-23 /pmc/articles/PMC9161906/ /pubmed/35465837 http://dx.doi.org/10.1080/21655979.2022.2064652 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Liang, Suiying Liu, Yueyang He, Jianhui Gao, Tian Li, Lanying He, Shanyang Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling |
title | Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling |
title_full | Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling |
title_fullStr | Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling |
title_full_unstemmed | Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling |
title_short | Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling |
title_sort | family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via tgf-β/smad2 signaling |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161906/ https://www.ncbi.nlm.nih.gov/pubmed/35465837 http://dx.doi.org/10.1080/21655979.2022.2064652 |
work_keys_str_mv | AT liangsuiying familywithsequencesimilarity46memberaconferschemoresistancetoovariancarcinomaviatgfbsmad2signaling AT liuyueyang familywithsequencesimilarity46memberaconferschemoresistancetoovariancarcinomaviatgfbsmad2signaling AT hejianhui familywithsequencesimilarity46memberaconferschemoresistancetoovariancarcinomaviatgfbsmad2signaling AT gaotian familywithsequencesimilarity46memberaconferschemoresistancetoovariancarcinomaviatgfbsmad2signaling AT lilanying familywithsequencesimilarity46memberaconferschemoresistancetoovariancarcinomaviatgfbsmad2signaling AT heshanyang familywithsequencesimilarity46memberaconferschemoresistancetoovariancarcinomaviatgfbsmad2signaling |